Inclusion Criteria:

- Patients must have pathologically-confirmed, previously untreated,stage
III-IV(excluding N3 or T4) squamous cell carcinoma of the oropharynx, without
evidence of distant metastasis

- Pretreatment tumor biopsy with sufficient tumor for HPV analysis is required. The
tumor must be HPV(+)/p16(+)

Smoking history <10 pack-year or equivalent (including cigarettes, cigars, pipes,
chewing tobacco, and/or marijuana) Smoking status definitions (National Health Interview
Survey and Behavioral Risk Factor Surveillance System (Nelson DE etal al, Am J Pub Health
2003;93:1335):

- Smokers: smoking now every day or some days in past month

- Quitters: at least 100 cigarettes/lifetime and not smoking in the past 1-12 months

- Former smoker: at least 100 cigarettes/lifetime and not smoking >12 months

- Never smokers: <100 cigarettes (or equivalent)/lifetime

- KPS > 80 (see Appendix A)

- Patients must undergo pre-treatment endoscopic tumor staging and PET-CT scanning

- Laboratory criteria:

- WBC > 3500/ul

- granulocyte > 1500/ul

- Platelet count > 100,000/ul

- Total Bilirubin < 1.5 X ULN

- AST and ALT < 2.5 X ULN

- Creatinine clearance >30 cc/min

- Patients must sign study specific informed consent

Exclusion Criteria:

- Prior head and neck malignancy or history of other prior non-head and neck malignancy
(excluding skin cancer and early stage treated prostate cancer) within the past 3
years

- Prior head and neck radiation or chemotherapy

- Any medical or psychiatric illness, which in the opinion of the principal
investigator, would compromise the patient's ability to tolerate this treatment or
limit compliance with study requirements

- Patients residing in prison

- Patients with prior anti-epidermal growth-factor receptor antibody therapy (antibody
or small molecule)